id,filing_uuid,filing_type,registrant_name,registrant_id,client_name,filing_year,filing_period,issue_code,specific_issues,government_entities,income_amount,expense_amount,is_no_activity,is_termination,received_date
1006971,da708c83-e61e-43d9-b2de-ccb53eee25d4,Q3,MCDERMOTT WILL & SCHULTE LLP,24338,ISIS PHARMACEUTICALS,2010,third_quarter,HCR,"Promote policies and legislation that foster medical research and development, as well as the antisense drug technology which promises relief from potential diseases including cancer, AIDs and diabetes.","HOUSE OF REPRESENTATIVES,SENATE",75000,,0,0,2010-10-19T17:23:25.097000-04:00
1006972,da708c83-e61e-43d9-b2de-ccb53eee25d4,Q3,MCDERMOTT WILL & SCHULTE LLP,24338,ISIS PHARMACEUTICALS,2010,third_quarter,PHA,"Promote policies and legislation that foster medical research and development, as well as the antisense drug technology which promises relief from potential diseases including cancer, AIDs and diabetes.","HOUSE OF REPRESENTATIVES,SENATE",75000,,0,0,2010-10-19T17:23:25.097000-04:00
1006973,da708c83-e61e-43d9-b2de-ccb53eee25d4,Q3,MCDERMOTT WILL & SCHULTE LLP,24338,ISIS PHARMACEUTICALS,2010,third_quarter,MED,"Promote policies and legislation that foster medical research and development, as well as the antisense drug technology which promises relief from potential diseases including cancer, AIDs and diabetes.","HOUSE OF REPRESENTATIVES,SENATE",75000,,0,0,2010-10-19T17:23:25.097000-04:00